With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.49679-45-0,Ethyl 3-chloroquinoxaline-2-carboxylate,as a common compound, the synthetic route is as follows.
EXAMPLE 8 Preparation of 3-(4-fluoro xaline-2-carboxamide (1) [00640] Ethyl 3-chloroquinoxaline-2-carboxylate (473.3 mg, 2.0 mmol), 4-fluorophenol (448.4 mg, 4.0 mmol) and Cs2C03 (1.30 g, 4.0 mmol) in NMP (5 mL) was stirred at 80 C for 16 hours. The reaction mixture was poured into water and the pH adjusted to 4 with aqueous IN HCl. The resulting precipitate was filtered off, taken up in MeOH (3 mL). Water (0.3 mL) and NaOH (320.0 mg, 8.00 mmol) were added and the reaction mixture was stirred at 40 C for 1 hour. The reaction mixture was diluted with IN HCl. The resulting precipitate was filtered, washed with ether, and dried to give 3-(4- fluorophenoxy)quinoxaline-2-carboxylic acid (120 mg, 21%) as a white solid. ESI-MS m/z calc. 284.06, found 285.3 (M+l)+; Retention time: 1.29 minutes (3 minutes run).
As the paragraph descriping shows that 49679-45-0 is playing an increasingly important role.
Reference£º
Patent; VERTEX PHARMACEUTICALS INCORPORATED; HADIDA-RUAH, Sara, Sabina; ANDERSON, Corey; ARUMUGAM, Vijayalaksmi; ASGIAN, Iuliana, Luci; BEAR, Brian, Richard; TERMIN, Andreas, P.; JOHNSON, James, Philip; WO2014/120815; (2014); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider